Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 1998

View Archived Issues

Company Profile: Millennium

Clinical development of LM-AS-013 advances at Green Cross

Inhibitors of the production or release of sCD23, TNF

Dopamine D4 receptor antagonists for imaging and therapy disclosed by Janssen

New excitatory amino acid antagonists in development at Pfizer

Meiji Seika describes 5-HT3 partial agonists for GI disorders

Triangle reports results from phase I/II FTC trial

Tsumura team reveals semisynthetic huperzine derivatives

More new agents for influenza from Lilly

PMPA reduces viral load in phase I/II

Potent, orally active inhibitor of kynurenine 3-hydroxylase discovered at Roche

Diphenylalkylamine derivative with cardioprotective properties characterized

ArQule and CuraGen establish broad drug discovery collaboration

Comparative trial of intracavernous alprostadil and MUSE for ED

Swiss Remune trials initiated

Long-term efficacy of epoprostenol for primary pulmonary hypertension

Optison imaging agent launched in U.S.

FDA advisory committee recommends Integrilin approval

Hybridon antitumor antisense compound enters clinical trials

Folic acid therapy and cardiovascular risk reduction

Anesta signs European marketing agreement for Actiq

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...